The immunohistochemistry (IHC) market is on a promising growth trajectory, with an anticipated value of USD 3.5 billion in ...

New breakthrough in mTBI. A study in rats has shown that light therapy could be a viable option for treating mTBI.

2024年10月3日，北京大学基础医学院罗建沅教授联合北京大学人民医院申占龙教授和丽水市中心医院纪建松教授课题组联合在PNAS杂志上发表了题为“LAMTOR1 ablation impedes cGAS degradation caused by ...

Astellas Pharma Inc. (ALPMY, ALPMY) said that the U.S. Food and Drug Administration has approved VYLOY (zolbetuximab-clzb) in ...

2024 年 10 月 3 日，北京大学基础医学院罗建沅教授联合北京大学人民医院申占龙教授和丽水市中心医院纪建松教授课题组联合在 PNAS 杂志上发表了题为 “LAMTOR1 ablation impedes cGAS degradation ...

This core facility provides high quality histological services and is available to assist investigators in the bone disease program within Texas Medical Center, as well as, researchers working with ...

Oxytocin neuron projections from two brain regions involved in parental care regulate both parental care and infanticidal behaviors in virgin mandarin voles.

"Roche’s VENTANA CLDN18 assay gains CE mark" was originally created and published by Medical Device Network, a GlobalData ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved VYLOY™ (zolbetuximab-clzb) in combination ...

VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct. 18 ...

CUT-Tag is used to identify super-enhancers (SEs) for the first time in gastric cancer, and the mRNA decay mechanism activated by SE-driven ZFP36L1 in infiltrative gastric cancer along with innovative ...